NCT06755047 3D Placental Volume in Placenta Accreta
| NCT ID | NCT06755047 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assiut University |
| Condition | Placenta Accreta |
| Study Type | OBSERVATIONAL |
| Enrollment | 38 participants |
| Start Date | 2024-12-31 |
| Primary Completion | 2025-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 38 participants in total. It began in 2024-12-31 with a primary completion date of 2025-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Placenta Accreta spectrum is a major obstetric disease nowadays. Different methods are used for antenatal diagnosis. In our study, investigators are aiming to compare 2 common ways for diagnosis, i.e; 3D Ultrasound and 2D with color Doppler.
Eligibility Criteria
Inclusion Criteria: * pregnant women with placenta previa Exclusion Criteria: * congenital anomalies of placenta Placental separation Uterine anomalies
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06755047 clinical trial?
This trial is open to female participants only, studying Placenta Accreta. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06755047 currently recruiting?
Yes, NCT06755047 is actively recruiting participants. Contact the research team at mohamedbeethoven2040@gmail.com for enrollment information.
Where is the NCT06755047 trial being conducted?
This trial is being conducted at Asyut, Egypt.
Who is sponsoring the NCT06755047 clinical trial?
NCT06755047 is sponsored by Assiut University. The trial plans to enroll 38 participants.